A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: Protocol optimization and best practices

Drug Discovery Today

Volumn 16, Issue 15-16, 2011, Pages 671-682

  Schwarz, Adam J ^a,b   Becerra, Lino ^a,e   Upadhyay, Jaymin ^a   Anderson, Julie ^a   Baumgartner, Richard ^a,c   Coimbra, Alexander ^a,c   Evelhoch, Jeff ^a,c   Hargreaves, Richard ^a,c   Robertson, Brigitte ^d   Iyengar, Smriti ^a,b   Tauscher, Johannes ^a,b   Bleakman, David ^a,b   Borsook, David ^a,e  

^a MCLEAN HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d SUNOVION PHARMACEUTICALS INC   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; DATA ANALYSIS; DECISION MAKING; DRUG DETERMINATION; DRUG DOSE; DRUG INDUSTRY; DRUG SYNTHESIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GOOD IMAGING PRACTICE; IMAGE ANALYSIS; IMAGING SYSTEM; INFORMATION PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; STANDARD;

BIOMARKERS, PHARMACOLOGICAL; DRUG DESIGN; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; QUALITY CONTROL;

EID: 80051669440     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.03.011     Document Type: Review

References (42)

1. P. Steiger Use of imaging biomarkers for regulatory studies J. Bone Joint Surg. Am. 91 Suppl. 1 2009 132 136
2. C.R. Jack Jr. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods J. Magn. Reson. Imaging 27 2008 685 691 (Pubitemid 351508080)
3. J. Jack Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 6 2010 212 220
4. M.O. Leach The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br. J. Cancer 92 2005 1599 1610 (Pubitemid 40756468)
5. M.O. Leach Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials Br. J. Radiol. 76 2003 S87 S91
6. L.J. Lesko Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81 2007 170 177 (Pubitemid 46174813)
7. J. Woodcock, and R. Woosley The FDA critical path initiative and its influence on new drug development Annu. Rev. Med. 59 2008 1 12 (Pubitemid 351287920)
8. G.D. Iannetti, and R.G. Wise BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn. Reson. Imaging 25 2007 978 988 (Pubitemid 47081371)
9. G.H. Glover Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR Magn. Reson. Med. 44 2000 162 167 (Pubitemid 30439852)
10. T.B. Jones Integration of motion correction and physiological noise regression in fMRI NeuroImage 42 2008 582 590
11. P. Bourel Automatic quality assessment protocol for MRI equipment Med. Phys. 26 1999 2693 2700 (Pubitemid 30007715)
12. L. Friedman, and G.H. Glover Report on a multicenter fMRI quality assurance protocol J. Magn. Reson. Imaging 23 2006 827 839 (Pubitemid 43825438)
13. T. Stocker Automated quality assurance routines for fMRI data applied to a multicenter study Hum. Brain Mapp. 25 2005 237 246 (Pubitemid 40734090)
14. A. Simmons Quality control for functional magnetic resonance imaging using automated data analysis and Shewhart charting Magn. Reson. Med. 41 1999 1274 1278 (Pubitemid 29247299)
15. J. Olsrud A two-compartment gel phantom for optimization and quality assurance in clinical BOLD fMRI Magn. Reson. Imaging 26 2008 279 286
16. L. Friedman Test-retest and between-site reliability in a multicenter fMRI study Hum. Brain Mapp. 29 2008 958 972
17. J.M. Ford Tuning in to the voices: a multisite FMRI study of auditory hallucinations Schizophr. Bull. 35 2009 58 66
18. S.G. Potkin, and J.M. Ford Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium Schizophr. Bull. 35 2009 15 18
19. R.A. Poldrack Guidelines for reporting an fMRI study Neuroimage 40 2008 409 414
20. C.S. Carter Optimizing the design and analysis of clinical functional magnetic resonance imaging research studies Biol. Psychiatry 64 2008 842 849
21. A.J. Schwarz A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements Drug Discov. Today 2011 doi:10.1016/j.drudis.2011.03.011
22. A. Verma Incorporating functional MRI into clinical pharmacology trials D. Borsook, Imaging in CNS Drug Discovery and Development 2010 Springer 153 162
23. E. George Evaluation of novel drugs using fMRI in early phase clinical trials: safety monitoring Drug Discov. Today 15 2010 684 689
24. S. Sossalla, and J.D. Schmitto Scientific teamwork - a particular approach Kardiol. Pol. 67 2009 1421 1423
25. S. Taneva Decoding the perioperative process breakdowns: a theoretical model and implications for system design Int. J. Med. Inform. 79 2010 14 30
26. M.V. Zeltser, and D.B. Nash Approaching the evidence basis for aviation-derived teamwork training in medicine Am. J. Med. Qual. 25 2010 13 23
27. R.G. Wise, and I. Tracey The role of fMRI in drug discovery J. Magn. Reson. Imaging 23 2006 862 876 (Pubitemid 43825441)
28. G.D. Mitsis Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result? Neuroimage 40 2008 121 132
29. Barch, D.M. and Mathalon, D.H. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol. Psychiatry 2011 Feb 18 [Epub ahead of print] doi:10.1016/j.biopsych.2011.01.004
30. E. Vul Puzzlingly high correlations in fMRI studies of emotion, personality and social cognition Perspect. Psychol. Sci. 4 2009 274 290
31. N. Kriegeskorte Circular analysis in systems neuroscience: the dangers of double dipping Nat. Neurosci. 12 2009 535 540
32. J. Suckling Components of variance in a multicentre functional MRI study and implications for calculation of statistical power Hum. Brain Mapp. 29 2008 1111 1122
33. P. Colombo Multicenter trial for the set-up of a MRI quality assurance programme Magn. Reson. Imaging 22 2004 93 101 (Pubitemid 38221587)
34. N.K. Logothetis What we can do and what we cannot do with fMRI Nature 453 2008 869 878 (Pubitemid 351832564)
35. S. Haller, and A.J. Bartsch Pitfalls in FMRI Eur. Radiol. 19 2009 2689 2706
36. S.G. Costafreda Multisite fMRI reproducibility of a motor task using identical MR systems J. Magn. Reson. Imaging 26 2007 1122 1126 (Pubitemid 47548177)
37. V.E. Gountouna Functional Magnetic Resonance Imaging (fMRI) reproducibility and variance components across visits and scanning sites with a finger tapping task NeuroImage 49 2010 552 560
38. B.B. Zandbelt Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size NeuroImage 42 2008 196 206
39. S.M. Smith Variability in fMRI: a re-examination of inter-session differences Hum. Brain Mapp. 24 2005 248 257 (Pubitemid 40327850)
40. R. Bosnell Reproducibility of fMRI in the clinical setting: implications for trial designs NeuroImage 42 2008 603 610
41. T. Tjandra Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design NeuroImage 27 2005 393 401 (Pubitemid 41074841)
42. A. Caceres Measuring fMRI reliability with the intra-class correlation coefficient NeuroImage 45 2009 758 768